Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?
| Autor: | Malcolm Whitehead, Jo Marsden, Mike Baum, Nigel Sacks, Roger A'Hern |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
medicine.medical_specialty Antineoplastic Agents Hormonal genetic structures medicine.medical_treatment Breast Neoplasms Pilot Projects Analogs & derivatives law.invention Breast cancer Randomized controlled trial law Surveys and Questionnaires Internal medicine medicine Humans Outpatient clinic Statistics & numerical data Aged Randomized Controlled Trials as Topic Aged 80 and over Gynecology Estradiol business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Hormone replacement therapy (menopause) Middle Aged Patient Acceptance of Health Care medicine.disease eye diseases Clinical trial Tamoxifen Reproductive Medicine Female sense organs business medicine.drug |
| Zdroj: | Fertility and Sterility. 73:292-299 |
| ISSN: | 0015-0282 |
| DOI: | 10.1016/s0015-0282(99)00510-5 |
| Popis: | Objective: To evaluate the feasibility of conducting a large randomized trial of HRT in symptomatic women with early-stage breast cancer. Design: Open randomized study. Setting: Outpatient clinics at The Royal Marsden and St. George's Hospitals, London. Patient(s): One hundred postmenopausal women with early-stage breast cancer, experiencing vasomotor symptoms and/or vaginal dryness. Intervention(s): Randomization (1:1) to HRT or no HRT for 6 months. Main Outcome Measure(s): Acceptance, continuance rates, and the reasons eligible women declined study entry. Result(s): Acceptance (38.8%) and continuance rates (>80%) were encouraging. The efficacy of HRT did not appear to be antagonized with concomitant tamoxifen. Seventy-five percent of women continued HRT after the study ended. Three women developed metastatic disease. Two used HRT. Conclusion(s): Despite informed consent, a national UK randomized trial of HRT should be feasible and has now been planned. Successful implementation necessitates the provision of information about HRT and the estrogen deficiency side effects of breast cancer therapy to health professionals and women with breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|